Skip to content

Abciximab

    Brands

    DEA Class; Rx

    Common Brand Names; ReoPro

    • Antiplatelet Agents, Cardiovascular; 
    • Glycoprotein IIb/IIIa Inhibitors

    Platelet glycoprotein IIb/IIIa receptor antagonist
    Adjunctive therapy for preventing cardiac ischemic complications in percutaneous coronary intervention (PCI) or in patients with unresponsive unstable angina
    Fab fragment of the chimeric monoclonal antibody 7E3

    Indicated for the Prevention of cardiac ischemic complications in patients undergoing PCI

    Indicated for prevention of cardiac complications in patients with unstable angina with PCI planned within 24 hr

    Adjunctive therapy during thrombolysis (off-label)

    Hypersensitivity

    Active internal bleeding

    Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance

    History of CVA (within 2 years) or CVA with a significant residual neurological deficit

    Bleeding diathesis

    Administration of oral anticoagulants within seven days unless prothrombin time is ≤1.2 times control

    Thrombocytopenia (< 100,000 cells/μL)

    Recent (within six weeks) major surgery or trauma

    Intracranial neoplasm, arteriovenous malformation, or aneurysm

    Severe uncontrolled hypertension

    Presumed or documented history of vasculitis

    • Bleeding, minor (70-82%)
    • Bleeding, major (17-21%)
    • Hypotension (14-21%)
    • Back pain (17.6%)
    • Nausea (13.6%)
    • Chest pain (11.4%)
    • Vomiting (7-11%)
    • Headache (6%)
    • Thrombocytopenia (2-6%)
    • Bradycardia (5%)
    • Injection site pain (3.6%)
    • Extremity pain (3.5%)
    • Abdominal pain (3%)
    • UTI (2%)
    • Dizziness (1.8%)
    • Peripheral edema (1.6%)
    • Anemia (1.2%)
    • Diarrhea (1%)
    • Hypoesthesia (1%)

    Intended for use with aspirin and heparin, and has only been studied in that setting

    Allergic reactions, some of which were anaphylaxis (sometimes fatal), reported rarely in patients receiving therapy; patients with allergic reactions should receive appropriate treatment; treatment of anaphylaxis should include immediate discontinuation of therapy and initiation of resuscitative measures

    In the event of serious uncontrolled bleeding or need for emergency surgery, therapy should be discontinued; if platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions

    Pregnancy Category: C

    Lactation: not known if excreted in breast milk; use caution

    Adults

    2,000 mg/day PO.

    Geriatric

    2,000 mg/day PO.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Abciximab

    injectable solution

    • 2mg/mL